Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/5/2026

1. NVDA
2. PCVX
3. SPY
4. PTC
5. MSFT
6. META
7. AMD
8. GMAB
9. AMZN
10. ATH

Go back to Syros Pharmaceuticals (SYRS) Tops Q4 EPS by 9c

Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

March 15, 2022 7:32 AM EDT

On Track to Report PK and Safety Data from Ongoing Dose Confirmation Study of SY-2101 in Mid-2022

Expect to Report Clinical Activity from the Safety Lead-In Portions of the Ongoing SELECT-AML-1 Trial of Tamibarotene and the Expansion Cohort of SY-5609 in Pancreatic Cancer in 2H 2022

Expect to Initiate Phase 1 Trial of SY-5609 in Hematologic Malignancies in 2H 2022

New Preclinical Data on CDK12 Inhibitor to be Presented at AACR; On Track to Name Next Development Candidate in 2H 2022

... More